Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1α

This publication has 23 references indexed in Scilit:

• The Krebs Cycle and Mitochondrial Mass Are Early Victims of Endothelial Dysfunction
  The American Journal of Pathology, 2009
• Cilostazol Protects Endothelial Cells Against Lipopolysaccharide-Induced Apoptosis Through ERK1/2- and P38 MAPK-Dependent Pathways
  The Korean Journal of Internal Medicine, 2009
• Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells
  Biochemical and Biophysical Research Communications, 2008
• LEF-1 activates the transcription of E2F1
  Biochemical and Biophysical Research Communications, 2008
• Endothelial Mitochondria
  Circulation Research, 2007
• Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion
  Brain Research, 2006
• Activation of AMP-Activated Protein Kinase Reduces Hyperglycemia-Induced Mitochondrial Reactive Oxygen Species Production and Promotes Mitochondrial Biogenesis in Human Umbilical Vein Endothelial Cells
  Diabetes, 2006
• Neuroprotective Effect of Cilostazol against Focal Cerebral Ischemia via Antiapoptotic Action in Rats
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
  Biochemical Pharmacology, 2000
• Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1
  Cell, 1999